Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr;23 Suppl 1(Suppl 1):S55-9.
doi: 10.1089/jamp.2009.0793.

The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation

David E Geller  1 , Kenneth C Kesser
Affiliations

The I-neb Adaptive Aerosol Delivery System enhances delivery of alpha1-antitrypsin with controlled inhalation

David E Geller et al. J Aerosol Med Pulm Drug Deliv. 2010 Apr.

Abstract

Background: Inhaled alpha1-antitrypsin (AAT) is being developed for treatment of cystic fibrosis to protect the lungs from excessive free elastase. High drug costs mandate a very efficient aerosol system to deliver a high payload to the airways. The I-neb Adaptive Aerosol Delivery (AAD) System is a portable, electronic, vibrating mesh nebulizer that delivers aerosol only during inhalation. It can be operated in conventional tidal breathing mode (TBM) or in target inhalation mode (TIM) that guides the patient to inhale deeply and slowly. The purposes of this in vitro study were to determine aerosol characteristics, device efficiency, and delivery time of AAT using the I-neb AAD System with TBM and TIM.

Methods: We studied the I-neb AAD System in TBM and TIM (inspiratory time 6 or 9 sec) using a breath simulator. The loaded dose was 0.5 mL AAT (50 mg/mL). Nebulized drug captured on an inspiratory filter was reported as emitted dose. Particle size was measured by laser diffraction. Predicted lung doses were calculated based on the results of a prior scintigraphy study of the I-neb AAD System.

Results: Particle size (VMD) for TBM and TIM was similar (4.4-4.8 microm). The emitted doses were very high and similar between modes (82-90% of loaded dose). Predicted lung dose of AAT (percent of loaded dose) and delivery times were: TBM 56.6% in 7.5 min; TIM-6 59.9% in 4.4 min; and TIM-9 64.5% in 2.5 min.

Conclusions: The I-neb AAD System enhanced AAT delivery by inhalation-only aerosol generation and a low-residual dose. Predicted lung dose was high for both TBM and TIM, but longer inspiratory times with TIM reduced the administration time to one-third that of tidal breathing. We conclude that slow, deep, controlled inspirations using the I-neb AAD System is an efficient method to deliver AAT.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
The I-neb Adaptive Aerosol Delivery (AAD) System.
FIG. 2.
FIG. 2.
Breath patterns for Tidal Breathing Mode (TBM) and Targeted Inhalation Mode (TIM) with 6- and 9-sec inspiratory times.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Chmiel JF. Konstan MW. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med. 2007;28:331–346. - PubMed
    1. Griese M. Kappler M. Gaggar A. Hartl D. Inhibition of proteases in cystic fibrosis lung disease. Eur Respir J. 2008;32:783–795. - PubMed
    1. Hubbard RC. Crystal RG. Strategies for aerosol therapy of alpha1-antitrypsin deficiency by the aerosol route. Lung Suppl. 1990;168:565–578. - PubMed
    1. McElvaney NG. Hubbard RC. Birrer P. Chernick MS. Caplan DB. Frank MM. Crystal RG. Aerosol α1-anti-trypsin treatment for cystic fibrosis. Lancet. 1991;337:392–394. - PubMed
    1. Berger M. Konstan MW. Hilliard JB. Aerosolized prolastin (α1-protease inhibitor) in CF. Pediatr Pulmonol. 1995;20:421.

Publication types